NID2 and central nervous system cancer: Here, we demonstrated that NID2 overexpression was an additional independent adverse prognostic factor for all gliomas, and it had an additive negative prognostic effect in addition to IDH mutation and 1p/19q codeletion status analyses for patient survival (Figure 3).